Tue. 16 Apr 2024, 3:46pm ET
Benzinga
Biotech, News, FDA, General
Alvotech receives FDA approval for Selarsdi for moderate to severe plaque psoriasis
Adult patients with:
- moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)
Pediatric patients 6 years and older with:
- moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)